DSruptive, a startup offering small, passive, sensor-equipped injectable subdermal implants that allow users to check their vital parameters, has secured an investment of € 400 000. The investment is a combination of cash and services from Nordic Group ApS. This is reported to also includes a follow up financing setup of an additional € 500 000.
DSruptive says the investment will be used to accelerate the development and to finance a large pre-clinical study of their innovative subdermal vital parameter monitoring platform.
“I am excited for our partnership with Nordic Group. As pioneers pushing a new paradigm in the field of digital health it is of critical importance for us to be working with investors who deeply understand how the industry is being transformed. Nordic Group is an entrepreneur founded and driven organisation and we feel a strong alignment both in values and in outlook.” says Hannes Sjöblad, co-founder of DSruptive
Chris Moore, CEO of Nordic Group, will join the board of directors of DSruptive as non-executive chairman.
“I am impressed by the business and technical proficiency of DSruptive’s team. The founders are leaders in their field and are already serving multiple international clients with advisory services relating to implantable platforms. This type of technology has huge global potential.” says Chris Moore of Nordic Group
Nordic Group is a company group within healthcare innovation and personalised medicine. The group includes a range of companies and brands supporting the advancement of healthcare innovation, including Nordic Clinic, Nordic Labs, Nordic Health, Athgene, DNA-Life, Medcheck, Resistomap and Thermocheck.